Solid lipid nanoparticles for pulmonary delivery of insulin

International Journal of Pharmaceutics

Volumn 356, Issue 1-2, 2008, Pages 333-344

  Liu, Jie ^a   Gong, Tao ^a   Fu, Hualin ^a,b   Wang, Changguang ^a,c   Wang, Xiuli ^a   Chen, Qian ^a   Zhang, Qin ^a   He, Qin ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN AGRICULTURAL UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Hypoglycemic effect; Insulin; Nebulization; Solid lipid nanoparticles

Indexed keywords

CHOLIC ACID; FLUORESCENT DYE; GLUCOSE; INSULIN; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; EMULSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVERSE MICELLE; SOYBEAN;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NANOPARTICLES; PHOSPHATIDYLCHOLINES; PULMONARY ALVEOLI; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHOLATE; SOYBEANS; TISSUE DISTRIBUTION;

EID: 42649135116     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.008     Document Type: Article

References (59)

1. Adjei A., and Gupta P. Pulmonary delivery of therapeutic peptides and proteins. J. Control. Release 29 (1994) 361-373
2. Almeida A.J., and Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59 (2007) 478-490
3. Callaghan C., and O'Barry P.W. The science of nebulised drug delivery. Thorax 52 (1997) S31-S44
4. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 13 (1996) 257-388
5. Chao Y.C., Chang S.F., Lu S.C., Hwang T.C., Hsieh W.H., and Liaw J.H. Ethanol enhanced in vivo gene delivery with non-ionic polymeric micelles inhalation. J. Control. Release 118 (2007) 105-117
6. Chattopadhyay P., Shekunov B.Y., Yim D., Cipolla D., Boyd B., and Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 59 (2007) 444-453
7. Choi W.S., Murthy G.G.K., Edwards D.A., Langer R., and Klibanov A.M. Inhalation delivery of proteins from ethanol suspensions. Proc. Natl. Acad. Sci. 98 (2001) 11103-11107
8. Çilek A., Çelebi N., Ti{dotless}rnaksi{dotless}z F., and Tay A. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm. 298 (2005) 176-185
9. Colthorpe P., Farr S.J., Taylor G., Smith I.J., and Wyatt D. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9 (1992) 764-768
10. Cui F.D., Shi K., Zhang L.Q., Tao A.J., and Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114 (2006) 242-250
11. Dahab R.A., Schäfer U.F., and Lehr C.M. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur. J. Pharm. Sci. 14 (2001) 37-46
12. Dalby R.N., and Tiano S.L. Pitfalls and opportunities in the inertial sizing and output testing of nebulizers. Pharm. Technol. 17 (1993) 144-156
13. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., and Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Release 86 (2003) 131-144
14. Damgé C., Maincent P., and Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117 (2007) 163-170
15. Desai T.R., Hancock R.E.W., and Finlay W.H. A facile method of delivery of liposomes by nebulization. J. Control. Release 84 (2002) 69-78
16. Elhissi A.M.A., Faizi M., Naji W.F., Gill H.S., and Taylor K.M.G. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334 (2007) 62-70
17. Eljamal M., Nagarajan S., and Patton J.S. In situ and in vivo methods for pulmonary delivery. In: Borchardt R.T., Smith P.L., and Wilson G. (Eds). Models for Assessing Drug Absorption and Metabolism (1996), Plenum Press, New York, NY 361-374 (Chapter 19)
18. European Pharmacopeia. Council of Europe. 5th ed. (2004), Strasbourg, France pp. 2799-2811
19. Gupta P.K., and Hickey A.J. Contemporary approaches in aerosolized drug delivery to the lung. J. Control. Release 17 (1991) 129-148
20. Hallworth G.W., and Westmorel D.G. The twin impinger: a simple devise for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J. Pharm. Pharmacol. 39 (1987) 966-972
21. Heinemann L., Klappoth W., Rave K., Hompesch B., Linkeschowa R., and Heis T. Intra-individual variability of metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23 (2000) 1343-1347
22. Huang Y.Y., and Wang C.H. Pulmonary delivery of insulin by liposomal carriers. J. Control. Release 113 (2006) 9-14
23. Hussain A., Arnold J.J., Khan M.A., and Ahsan F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94 (2004) 15-24
24. Johannson F., Hjertberg E., Eirefelt S., Tronde A., and Bengtsson U.H. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur. J. Pharm. Sci. 17 (2002) 63-71
25. Kanaoka E., Nagata S., and Hirano K. Stabilization of aerosolized IFN-γ by liposomes. Int. J. Pharm. 188 (1999) 165-172
26. Karathanasis E., Ayyagari A.L., Bhavane R., Bellamkonda R.V., and Annapragada A.V. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J. Control. Release 103 (2005) 159-175
27. Kawashima Y., Yamamoto H., Takeuchi H., Fujioka S., and Hino T. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control. Release 62 (1999) 279-287
28. Kumar T.R., Soppimath K., and Nachaegari S.K. Novel delivery technologies for protein and peptide therapeutics. Curr. Pharm. Biotechnol. 7 (2006) 261-276
29. Laube B.L., Georgopoulus A., and Adams G.K. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. J. Am. Med. Assoc. 269 (1993) 2106-2107
30. Li M.G., Lu W.L., Wang J.C., Zhang X., Wang X.Q., Zheng A.P., and Zhang Q. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats. Int. J. Pharm. 329 (2007) 182-191
31. Li Y.P., and Mitra A.K. A simple method of correlating pharmacodynamic equivalence with absolute bioavailability following noninvasive delivery of insulin. Pharm. Res. 11 (1994) 1505-1508
32. Li Y.P., and Mitra A.K. Effects of phospholipids chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm. Res. 13 (1996) 76-79
33. Liu F., Shao Z., Kildsig D.O., and Mitra A.K. Pulmonary delivery of free and liposomal insulin. Pharm. Res. 10 (1993) 228-232
34. Liu J., Gong T., Wang C.G., Zhong Z.R., and Zhang Z.R. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int. J. Pharm. 340 (2007) 153-162
35. Malcolmson R.J., and Embleton J.K. Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today 1 (1998) 298-394
36. Malik D.K., Baboota S., Ahuja A., Hasan S., and Ali J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4 (2007) 141-151
37. Matilainen L., Järvinen K., Toropainen T., Näsi E., Auriola S., Järvinen T., and Jarho P. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int. J. Pharm. 318 (2006) 41-48
38. McCallion O.N.M., Taylor K.M.G., Thomas M., and Taylor A.J. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm. Res. 12 (1995) 1682-1688
39. McCallion O.N.M., Taylor K.M.G., Thomas M., and Taylor A.J. The influence of surface tension on aerosols produced by medical nebulisers. Int. J. Pharm. 129 (1996) 123-136
40. Mendes P.J., Pinto J.F., and Sousa J.M.M. A non-dimensional functional relationship for the fine particle fraction produced by dry powder inhalers. Aerosol Sci. 38 (2007) 612-624
41. Morçöl T., Nagappan P., Nerenbaum L., Mitchell A., and Bell S.J.D. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277 (2004) 91-97
42. Morishita M., Goto T., Nakamura K., Lowman A.M., Takayama K., and Peppas N.A. Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in types 1 and 2 diabetic rats. J. Control. Release 110 (2006) 587-594
43. Nguyen H., and Bouwstra J.A. Vesicles as tool for transdermal and dermal delivery. Drug Discov. Today: Technol. 2 (2005) 67-74
44. Niven R.W., Speer M., and Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm. Res. 8 (1991) 217-221
45. Pandey R., and Khuller G.K. Solid lipid particle-based inhalable sustained drug delivery against experimental tuberculosis. Tuberculosis 85 (2005) 227-234
46. Park S.H., Kwon J.H., Lim S.H., Park H.W., and Kim C.W. Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. Int. J. Pharm. 339 (2007) 205-212
47. Patton J.S., Fishburn C.S., and Weers J.A. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 1 (2004) 338-344
48. Roche N., and Huchon G.J. Rationale for the choice of an aerosol delivery system. J. Aerosol Med. 13 (2000) 393-404
49. Rudolph C., Schillinger U., Ortiz A., Tabatt K., Plank C., Müller R.H., and Rosenecker J. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 21 (2004) 1662-1669
50. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58 (2006) 1030-1060
51. Sakr F.M. A new approach for insulin delivery via the pulmonary route: design and pharmacokinetics in non-diabetic rabbits. Int. J. Pharm. 86 (1992) 1-7
52. Scheuch G., Kohlhaeufl M.J., and Siekeier P.B.R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 58 (2006) 996-1008
53. Sun X., and Zhang Z.R. Optimizing the novel formulation of liposome-polycation-DNA complexes (LPD) by central composite design. Arch. Pharm. Res. 27 (2004) 797-805
54. Suzuki A., Morishita M., and Kajita M. Enhanced colonic and rectal absorption of insulin using the multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid. J. Pharm. Sci. 87 (1998) 1196-1202
55. Taylor K.M.G., Taylor G., Kellaway I.W., and Stevens J. The stability of liposomes to nebulisation. Int. J. Pharm. 58 (1990) 57-61
56. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., and Almeida A.J. Lymphatic uptake of pulmonary delivered solid lipid nanoparticles. J. Drug Target. 10 (2002) 607-613
57. Waldrep J.C., Scherer P.W., Keyhani K., and Knight V. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int. J. Pharm. 97 (1993) 205-212
58. Zaru M., Mourtas S., Klepetsanis P., Fadda A.M., and Antimisiaris S.G. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 67 (2007) 655-666
59. Zhang Q., Shen Z.C., and Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int. J. Pharm. 218 (2001) 75-80